American College of Neuropsychopharmacology Inc. Neuropsychopharmacology
subscribe to npp
SEARCH
Advanced search
My Account E-alerts Subscribe Register Help
Journal home
Current Issue
Advance Online Publication
Archive
Online sample issue FREE!
Author index
Keyword index
For authors
Editorial Board
Instructions for authors
Aims and scope
Indexed in
Author queries
Online Submission
Customer Services
Subscription information
Journal prices
Order sample issue
Purchase articles,
reprints & permissions
Advertising
Contact NPG
nature.com
Neuropsychopharmacology (1995) 12 159-165.

Fluoxetine and Oculomotor Activity during Sleep in Depressed Patients

Roseanne Armitage Ph.D, Madhukar Trivedi MD and John A Rush MD
The University of Texas Southwestern Medical Center at Dallas, TX

Correspondence: Roseanne Armitage, Ph.D, The University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75235-9070

ABSTRACT

The effects of fluoxetine on automated measures of electrooculographic (EOG) and electromyographic (EMG) activity were evaluated in 41 patients with nonpsychotic, major depressive disorder. Sleep EEG evaluations were conducted at baseline, while patients were symptomatic and unmedicated, and following four to five weeks of treatment with fluoxetine (20 mg). The number of eye movements (> 75 muV) and the amplitude of EOG and EMG activity increased significantly on treatment in REM, stages 1, 2, and slow-wave sleep. All patients showed EOG and EMG abnormalities in at least one stage of sleep. Thirty-four percent of patients showed increased EOG and EMG activity on treatment in every sleep stage. It is suggested that fluoxetine-induced oculomotor abnormalities are likely to be the result of increased availability of serotonin and secondary dopaminergic effects.

Keywords: Sleep; Depression; Antidepressants; Fluoxetine
  top go to top
Article Links
Send to a friend Send to a friend
Download PDF Download PDF
 Next Article Next Article
 Previous Article Previous Article
 Table of Contents Table of Contents
Privacy Policy Copyright © 1995 by the American College of Neuropsychopharmacology